CYTOO runs myotoxicity in the same system, on the same donors, with the same readouts, benchmarked against a reference myotoxicity compound library.
Published
Signal category
Research & Knowledge
Quote
“And we run myotoxicity in the same system, on the same donors, with the same readouts, benchmarked against a reference myotoxicity compound library.”
— CYTOO team
Company
- Industry
- Biotechnology Research
- Location
- Grenoble, FR
- Company size
- 28 employees
CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.
Founded 2008